Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Cancer Res. 2022 Mar 1;82(5):885–899. doi: 10.1158/0008-5472.CAN-21-1230

Figure 6. Anti-Jagged-1 blockade delays tumor recurrence.

Figure 6.

A) Workflow of tumor generation, treatment with the anti-Jagged-1 (α-Jag1) blockade, and tumor harvest for scRNA seq. Tumors were treated with α-Jag1 or the control α-IgG (15mg/kg) once a week for 5 weeks and then treatment was stopped. The majority of tumors were called “recurrent” when they reached 5mm in diameter (12 out of 20 total mice). B) Survival graph showing α-Jag1 delays tumor recurrence, median survival of 222 days for α-Jag1 vs. 52.5 days for α-IgG. A few older mice died of unknown cases (8 out of 20 total mice). The p-value from a log rank test is shown. C) Pie chart of different cell types after α-IgG or α-Jag1 treatments. D) IF staining of cancer cells (GFP), CD4 and CD8 T cells, Tregs (Foxp3), macrophages, and MDSCs